CanadaBuys #W6369-27-A062

Canadian DND procurement of Ca-DTPA ampoules for radiological exposure treatment

Canada’s Department of National Defence is seeking a radiological-contamination treatment medicine for Canadian Armed Forces health services. - Buyer: Government of Canada, Department of National Defence (DND), through the Strategic Medical Countermeasures Program, on behalf of the Canadian Forces Health Services Group. - OEM: Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG, identified as the only currently known capable supplier. - Requested product: 750 Calcium Trisodium Pentetate (Ca-DTPA) ampoules, with an option for up to 500 additional ampoules; no part number is specified. - Each ampoule must contain a sterile intravenous solution of 1,000–1,055 mg Ca-DTPA in 5 mL. - Intended to treat known or suspected internal contamination from radiological agents, including transuranic elements. - Key requirements: Valid authorization from an accepted regulator; documentation supporting the active ingredient and treatment indication; at least 36 months of shelf life backed by stability data; and compliance with operational, quality, packaging, storage, and labelling requirements. - Supply timing: Three firm delivery tranches of 250 ampoules each over the first three years; the option for up to 500 more may be exercised during the contract term. Other suppliers may demonstrate their ability to meet all requirements.

Description

The Department of National Defence seeks 750 Calcium Trisodium Pentetate (Ca-DTPA) ampoules to treat Canadian Armed Forces personnel who may have been exposed to radiological agents, with an option for up to 500 additional ampoules. The product must be a sterile intravenous solution containing 1,000–1,055 mg of Ca-DTPA in a 5 mL ampoule and meet specified authorization, quality, packaging, storage, and shelf-life requirements. Deliveries include 250 ampoules by March 1, 2027, followed by 250 in each of fiscal years 2027–2028 and 2028–2029. This Advance Contract Award Notice identifies Heyl Chem.-pharm. Fabrik GmbH & Co. KG as the only currently known supplier; other suppliers may submit a Statement of Capabilities by the closing date.

View original listing